Filing Flows › Xilio Therapeutics (XLO) › Q2 2025
Xilio Therapeutics (XLO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Xilio Therapeutics (XLO) reported revenue of $8.1M for the second quarter 2025 (Q2 2025), +243% from a year earlier and +176% from the quarter before. Operating margin was -177.7%, net loss $15.8M (196.0% of revenue).
Xilio Therapeutics, Q2 2025: revenue $8.1M (+243% year over year), operating margin -177.7%, net loss $15.8M, operating cash flow −$14.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.1M | +176% | +243% |
| Operating profit | −$14.4M | — | — |
| Net earnings | −$15.8M | — | — |
| Operating cash flow | −$14.5M | -150% | — |
What changed
Revenue was $8.1M in Q2 2025, up 243% year over year and up 176% from the previous quarter.
Operating costs exceeded revenue by $14.4M, an operating margin of -177.7%. Total costs grew 32% against revenue growth of 243%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $15.8M, wider than the previous quarter's $13.3M loss.
Operating cash flow was −$14.5M. Non-cash charges added back $381K of depreciation and amortization and $1.4M of share-based compensation. Capital expenditures of $401K exceeded it, leaving free cash flow of −$14.9M.
Questions
What was Xilio Therapeutics' revenue in the second quarter 2025?
Xilio Therapeutics (XLO) reported revenue of $8.1M for the second quarter 2025 (Q2 2025), +243% from a year earlier and +176% from the quarter before.
Was Xilio Therapeutics profitable in the second quarter 2025?
Operating loss was $14.4M (-177.7% of revenue) and net loss $15.8M.
Source: Xilio Therapeutics 10-Q on SEC EDGAR.